EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Chimeric antigen receptor natural killer cell therapy for solid tumors: mechanisms, clinical progress, and strategies to overcome the tumor microenvironment

Yu Xiang, Jiayi Dong, Lijuan Shao, Size Chen

Experimental Biology and Medicine · 19.12.2025 · 250

DOI: 10.3389/ebm.2025.10841 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Experimental Biology and Medicine, online erschienen am 19.12.2025. Verfasst von Yu Xiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immuno-Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, Guangzhou, …. Hauptthemen laut MEDLINE: Killer Cells, Natural, Neoplasms, Tumor Microenvironment, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Natural killer (NK) cells represent a fundamental component of the innate immune system, endowed with the ability to identify and eradicate virus-infected and malignant cells. The advent of chimeric antigen receptor (CAR) technology has introduced innovative strategies for augmenting the antitumor potential of natural killer (NK) cells. Chimeric antigen receptor natural killer (CAR-NK) cells exert dual cytotoxic effects against tumor cells through CAR-mediated antigen-specific recognition in concert with the nonspecific cytolytic activity mediated by intrinsic NK receptors. This review critically evaluates the clinical progression of CAR-NK cells specifically against solid tumors, focusing on mechanisms to overcome the immunosuppressive tumor microenvironment (TME), the complexity of allogeneic manufacturing, and the latest engineering strategies for enhanced homing and persistence. Specifically, we emphasize the urgent need for robust Phase II/III clinical data and standardized Good Manufacturing Practice (GMP) protocols to realize the full potential of off-the-shelf allogeneic CAR-NK therapies. Additionally, we examine technological advancements and emerging directions addressing persistent challenges in this domain to offer theoretical underpinnings and research perspectives for the clinical deployment of CAR-NK cell therapy in solid tumor management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalNeoplasmsTumor MicroenvironmentReceptors, Chimeric AntigenImmunotherapy, AdoptiveHumansAnimals

Stichwörter der Autor:innen

chimeric antigen receptor natural killer cellsgene editingimmunotherapysolid tumorstumor microenvironment

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Immuno-Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, Guangzhou, China.
  • Guangdong Provincial Engineering Research Center for Precision Medicine in Esophageal Cancer, Guangdong Pharmaceutical University, Guangzhou, China.
  • Key Laboratory of Monitoring Adverse Reactions Associated with Chimeric Antigen Receptor T-Cell Therapy, Guangdong Higher Education Institutions, Guangdong Pharmaceutical University, Guangzhou, China.
  • Key Laboratory of Cancer Immunotherapy, Guangdong Higher Education Institutions, Guangdong Pharmaceutical University, Guangzhou, China.
  • School of Clinical Medicine, Guangdong Pharmaceutical University, Guangzhou, China.

Zitieren

APA

Xiang, Y., Dong, J., Shao, L., & Chen, S. (2025). Chimeric antigen receptor natural killer cell therapy for solid tumors: mechanisms, clinical progress, and strategies to overcome the tumor microenvironment. Experimental Biology and Medicine, 250. https://doi.org/10.3389/ebm.2025.10841

Vancouver

Xiang Y, Dong J, Shao L, Chen S. Chimeric antigen receptor natural killer cell therapy for solid tumors: mechanisms, clinical progress, and strategies to overcome the tumor microenvironment. Experimental Biology and Medicine. 2025;250. doi:10.3389/ebm.2025.10841

BibTeX
@article{Xiang2025,
  author = {Xiang, Yu and Dong, Jiayi and Shao, Lijuan and Chen, Size},
  title = {Chimeric antigen receptor natural killer cell therapy for solid tumors: mechanisms, clinical progress, and strategies to overcome the tumor microenvironment},
  journal = {Experimental Biology and Medicine},
  year = {2025},
  volume = {250},
  doi = {10.3389/ebm.2025.10841}
}
Kostenlos starten →